CytomX expands Regeneron bispecific cancer therapy collaboration, receives $37 million payment

CytomX Therapeutics, Inc.
Regeneron Pharmaceuticals, Inc.

CytomX Therapeutics, Inc.

CTMX

0.00

Regeneron Pharmaceuticals, Inc.

REGN

0.00
  • CytomX expanded its collaboration and licensing deal with Regeneron to develop conditionally activated bispecific cancer therapies.
  • Regeneron will fund preclinical and clinical development, as well as commercialization, for programs covered under the expanded agreement.
  • CytomX will receive a USD 37 million target selection payment tied to two additional programs.
  • Regeneron secured an option to select up to six additional future targets.
  • Milestones across nomination, development, regulatory, and sales could total about USD 4 billion; CytomX is also eligible for tiered global net sales royalties.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytomX Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606030800PRIMZONEFULLFEED9730821) on June 03, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.